Senolytics + NMN: Cell Clearance and NAD+ Replenishment Stack
Expert Summary
NMN and senolytics have become the most commonly combined longevity intervention pair, partly because their mechanisms are complementary and partly because human evidence exists for both. The combination addresses what many aging researchers consider the two most tractable hallmarks of aging: NAD+ decline and senescent cell accumulation.
Key Facts
- Why they pair well: NMN raises NAD+ in all cells including senescent ones. Senolytics eliminate the senescent cells. The order-of-operations: senolytics first (clear drains) then NMN (fill the pool) maximizes NAD+ improvement per dose.
- Timing: NMN: daily morning. Fisetin senolytic: 2 days per month. On senolytic burst days, take NMN as usual (no conflict). Quercetin (CD38 inhibitor, complements NMN): daily continuous.
- Expected outcome: Studies predict a 20–40% additional increase in tissue NAD+ from senolytic treatment on top of NMN alone — primarily from eliminated senescent cell NAD+ consumption.
- Cellular response: With higher NAD+, SIRT1/3/6 activity increases — restoring DNA repair, mitochondrial biogenesis, and inflammatory gene suppression. The senolytics remove the largest NAD+ consumers; NMN fills the freed capacity.
- Cost optimization: NMN is the most expensive component (~$1–3/day). Reducing senescent cell NAD+ consumption via senolytics may allow equivalent NAD+ outcomes at lower NMN doses — potentially reducing NMN cost while maintaining benefits.
Recommended Products
Frequently Asked Questions
Should I take NMN on senolytic burst days?
Yes. Continue NMN on burst days. There is no pharmacokinetic conflict, and maintaining NAD+ during the senolytic event may help healthy cells survive any bystander inflammatory signal from dying senescent cells.
Is NR (nicotinamide riboside) interchangeable with NMN here?
Yes. NR and NMN both effectively raise NAD+ via the salvage pathway. NR is typically lower cost per effective dose. Either works as the NAD+ component of this stack.
Scientific References
- Yoshino J et al. NMN treats diet-induced diabetes. Cell Metabolism. 2011. PMID: 21982712
- Kirkland JL et al. The clinical potential of senolytic drugs. Journal of the American Geriatrics Society. 2017. PMID: 28869295